Zhang Liqiang, Yaron Jordan R, Ambadapadi Sriram, Lucas Alexandra
Center for Personalized Diagnostics and Center for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler St, Tempe, AZ, 85287, USA.
Drug Metabolism and Pharmacokinetics, Pharmacyclics LLC, Sunnyvale, CA, USA.
Methods Mol Biol. 2018;1826:133-142. doi: 10.1007/978-1-4939-8645-3_9.
Serpins function as a trap for serine proteases, presenting the reactive center loop (RCL) as a target for individual proteases. When the protease cleaves the RCL, the serpin and protease become covalently linked leading to a loss of function of both the protease and the serpin; this suicide inhibition is often referred to as a "mouse trap." When the RCL P1-P1' scissile bond is cut by the protease, the resulting bond between the protease and the RCL leads to insertion of the cleaved RCL into the β-sheet A and relocation of the protease to the opposite pole of the serpin, forming a suicide complex. Only a relatively small part of the serpin molecule can be removed in deletion mutations before the serpin RCL inhibitory function is lost. Serpin RCL peptides have been developed to block formation of serpin aggregates in serpinopathies, genetic serpin mutations wherein the abnormal serpins insert their RCL into adjacent serpins forming aggregates of inactive serpins.We have further posited that this natural cleavage site in the serpin RCL may form active serpin metabolites with potential to add to the serpin's inhibitory functions. We have developed RCL peptides based upon predicted serpin RCL cleavage (or metabolism) sites and tested these serpins for inhibitory function. In this chapter we describe the development of RCL-derived peptides, peptides derived based upon the RCL sequences of two myxomaviral serpins. Methods used to develop peptides are described for RCL-derived peptides from Serp-1, a thrombotic and thrombolytic serine protease inhibitor, and Serp-2, a cross class serine and cysteine protease inhibitor (Subheadings 2.1 and 3.1). Approaches to testing RCL peptide functions, in vitro by molecular assays and in vivo in models of cell migration, MHV-68 infection, and aortic allograft transplant are described (Subheadings 2.2 and 3.2).
丝氨酸蛋白酶抑制剂(Serpins)作为丝氨酸蛋白酶的陷阱,将反应中心环(RCL)作为单个蛋白酶的作用靶点。当蛋白酶切割RCL时,丝氨酸蛋白酶抑制剂和蛋白酶会共价连接,导致蛋白酶和丝氨酸蛋白酶抑制剂的功能丧失;这种自杀抑制通常被称为“捕鼠器”。当蛋白酶切割RCL的P1 - P1' 可裂解键时,蛋白酶与RCL之间形成的键会导致切割后的RCL插入β - 折叠A中,并使蛋白酶重新定位到丝氨酸蛋白酶抑制剂的相对极,形成自杀复合物。在丝氨酸蛋白酶抑制剂RCL抑制功能丧失之前,只有相对较小部分的丝氨酸蛋白酶抑制剂分子可以在缺失突变中被去除。丝氨酸蛋白酶抑制剂RCL肽已被开发用于阻止丝氨酸蛋白酶病中丝氨酸蛋白酶抑制剂聚集体的形成,丝氨酸蛋白酶病是一种遗传性丝氨酸蛋白酶抑制剂突变,其中异常的丝氨酸蛋白酶抑制剂将其RCL插入相邻的丝氨酸蛋白酶抑制剂中,形成无活性丝氨酸蛋白酶抑制剂的聚集体。我们进一步推测,丝氨酸蛋白酶抑制剂RCL中的这个天然切割位点可能形成具有潜在活性的丝氨酸蛋白酶抑制剂代谢产物,从而增强丝氨酸蛋白酶抑制剂的抑制功能。我们基于预测的丝氨酸蛋白酶抑制剂RCL切割(或代谢)位点开发了RCL肽,并测试了这些丝氨酸蛋白酶抑制剂的抑制功能。在本章中,我们描述了基于两种黏液瘤病毒丝氨酸蛋白酶抑制剂的RCL序列衍生的RCL肽的开发。描述了用于从血栓形成和溶栓丝氨酸蛋白酶抑制剂Serp - 1和跨类丝氨酸和半胱氨酸蛋白酶抑制剂Serp - 2开发RCL衍生肽的肽开发方法(小标题2.1和3.1)。描述了通过分子测定在体外以及在细胞迁移、MHV - 68感染和主动脉同种异体移植模型中体内测试RCL肽功能的方法(小标题2.2和3.2)。